Kodiak Hub CEO Malin Schmidt Nominated for SaaSiest CEO of the Year
6.5.2025 11:00:00 CEST | Business Wire | Press Release
Kodiak Hub, an AI-powered supplier relationship management (SRM) platform, today announced that CEO Malin Schmidt is nominated for SaaSiest CEO of the Year, a peer-voted honor spotlighting the most visionary and impactful leaders in European Software as a Service (SaaS).
Schmidt is one of four finalists selected by the SaaSiest CEO Network, an invite-only community of SaaS leaders across the European region. The award celebrates founders and executives who’ve scaled high-growth businesses while contributing meaningfully to the broader SaaS ecosystem.
As CEO of Kodiak Hub, Schmidt is redefining SRM—a space long dominated by legacy suites—with an AI-powered platform that helps companies make faster, smarter decisions so they can drive performance, consistency and real-world impact. Under her leadership, Kodiak has expanded into the U.S. market with $12 million in funding, fueling the company’s expansion and growth across its manufacturing, industrial and food & beverage customer base.
“We built Kodiak Hub to help businesses navigate global supply chains, enabling smarter buying decisions in a very turbulent global trade landscape,” said Malin Schmidt, CEO of Kodiak Hub. “Being named alongside Europe’s top SaaS leaders validates the impact we’re making and pushes us to keep raising the bar on how companies stay competitive in their markets and drive top-line growth.”
Kodiak Hub uses AI and automation to help procurement teams make sense of scattered supplier data, automate tasks like intake and qualification, track performance in real time and provide clear recommendations to reduce risk and move faster.
The winner will be announced live on May 6th at SaaSiest 2025 in Malmö, Sweden. As part of the event, Schmidt will lead a keynote session onstage titled: “The CEO´s Guide to Cracking the Enterprise Code”.
For more information about the SaaSiest and Malin Schmidt’s keynote, visit www.saasiest2025.com
About Kodiak Hub
Kodiak Hub, founded in 2016, operating across Europe & Headquartered in Stockholm, Sweden, is a provider of a cloud-based Supplier Relationship Management (SRM) SaaS empowering global procurement teams to source smarter - powering sustainable supplier relationships.
Kodiak Hub offers a modular suite of SRM solutions that teams can plug n’ play and an end-to-end platform that enables buyers, category managers, and procurement teams to drive operational, tactical and strategic business value. With features like automated supplier intake and qualification, performance monitoring, and management, and buyer-supplier innovation, Kodiak Hub transforms how teams manage supplier relationships. Teams that use Kodiak Hub power Performance, Predictability, and Purpose in global supply chains.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250506754396/en/
Contacts
Media Contact
Corporate Ink for Kodiak Hub
kodiakhub@corporateink.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom